Home›Trial›NCT06608927
NCT06608927Phase 3ACTIVE NOT RECRUITING

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Study Summary

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.

Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions / Drugs
QuemliclustatPlaceboNab-paclitaxelGemcitabine
View on ClinicalTrials.gov ↗
Sponsor
ARQT
Arcus Biosciences
Immuno-Oncology
F31/100
Study Details
Enrollment610 participants
Primary Completion—
Lead SponsorArcus Biosciences, Inc.
Data Retrieved2026-04-11 02:54:25.662861+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 610 participants
Sponsor Catalyst Profile

Arcus Biosciences (ARQT) is the sponsoring company for this trial. BiotechSign currently grades this company F (31/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ARQT Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.